View in EDS

1197TiP A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation

Saved in:
Bibliographic Details
Title: 1197TiP A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation
Authors: Lee, D.H.1 (AUTHOR), Roohullah, A.2 (AUTHOR), Cho, B.C.3 (AUTHOR), Lee, S-H.4 (AUTHOR), Lemech, C.5 (AUTHOR), de Souza, P.6 (AUTHOR), Millward, M.7 (AUTHOR), Choi, J.8 (AUTHOR), Park, K.E.8 (AUTHOR), Kim, E.8 (AUTHOR), Kim, N.Y.8 (AUTHOR), Shin, Y.K.9 (AUTHOR), Han, J-Y.10 (AUTHOR)
Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1096-S1096. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2022.07.1320